Jump Financial LLC purchased a new position in UiPath Inc. (NYSE:PATH - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 40,104 shares of the healthcare company's stock, valued at approximately $996,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of UiPath by 7.6% during the 3rd quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company's stock valued at $645,916,000 after purchasing an additional 2,673,718 shares in the last quarter. Glenmede Trust Co. NA boosted its holdings in UiPath by 3,273.3% during the third quarter. Glenmede Trust Co. NA now owns 1,564,985 shares of the healthcare company's stock worth $26,777,000 after buying an additional 1,518,592 shares in the last quarter. Vestmark Advisory Solutions Inc. bought a new position in shares of UiPath in the fourth quarter valued at $15,543,000. FMR LLC increased its holdings in shares of UiPath by 2.9% in the third quarter. FMR LLC now owns 16,238,176 shares of the healthcare company's stock valued at $277,835,000 after buying an additional 463,032 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in shares of UiPath by 179.9% during the 3rd quarter. Los Angeles Capital Management LLC now owns 715,688 shares of the healthcare company's stock valued at $12,245,000 after acquiring an additional 459,965 shares during the last quarter. 62.50% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on PATH shares. BMO Capital Markets boosted their target price on UiPath from $24.00 to $28.00 and gave the stock a "market perform" rating in a research report on Thursday, March 14th. Canaccord Genuity Group lifted their target price on shares of UiPath from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, March 15th. Needham & Company LLC restated a "buy" rating and issued a $30.00 price target on shares of UiPath in a research report on Wednesday, March 20th. Barclays lifted their price objective on shares of UiPath from $23.00 to $25.00 and gave the stock an "equal weight" rating in a research report on Friday, March 15th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $29.00 target price on shares of UiPath in a report on Monday, April 1st. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $27.41.
View Our Latest Stock Analysis on PATH
UiPath Trading Up 1.1 %
Shares of UiPath stock traded up $0.22 during mid-day trading on Friday, reaching $20.41. 5,148,220 shares of the stock were exchanged, compared to its average volume of 5,293,439. The firm has a 50-day simple moving average of $21.05 and a 200 day simple moving average of $22.04. UiPath Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $27.87. The company has a market cap of $11.61 billion, a price-to-earnings ratio of -120.05 and a beta of 1.01.
UiPath (NYSE:PATH - Get Free Report) last announced its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.10. The company had revenue of $405.25 million during the quarter, compared to analyst estimates of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. On average, research analysts predict that UiPath Inc. will post -0.04 EPS for the current fiscal year.
Insider Transactions at UiPath
In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $19.79, for a total value of $791,600.00. Following the transaction, the chief financial officer now directly owns 946,848 shares in the company, valued at approximately $18,738,121.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have sold 96,000 shares of company stock worth $2,023,440. Corporate insiders own 22.37% of the company's stock.
UiPath Company Profile
(
Free Report)
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Featured Articles
Before you consider UiPath, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.
While UiPath currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
